Director/PDMR Shareholding

RNS Number : 8679R
Rentokil Initial PLC
31 October 2019
 

Rentokil Initial plc (the Company)

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

Daragh Fagan

 

2

 

Reason for the notification

 

a)

 

Position/status

 

Group General Counsel & Company Secretary

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Rentokil Initial plc

b)

 

LEI

 

549300VN4WV7Z6T14K68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 1p each

 

 

ISIN: GB00B082RF11

b)

 

Nature of the transaction

 

 

Sale of shares.

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

455.00356

15,000

454.854

5,000

456.6

10,000

456.1011

10,000

456.4

10,000

456.95724

5,000

458.21884

10,000

458.5

5,000

458.00062

5,000

458.01278

5,000

458.6

10,000

458.537607

10,000

 

 

d)

 

Aggregated information

 

- Aggregated volume

 

- Aggregated price

 

 

 

100,000

 

457.209458p

 

e)

 

Date of the transaction

 

31 October 2019

f)

 

Place of the transaction

 

London Stock Exchange (XLON)

 

Enquiries:

 

Catherine Stead, Deputy Company Secretary              Rentokil Initial plc             01276 607444

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBUBDGDUXBGCB
UK 100